Connect with others who understand.

  •   Learn from expert-reviewed resources
  •   Real advice from people who’ve been there
  •   People who understand what you’re going through
Sign Up Log In
All Resources Treatments A-Z Personal Assistant What is This Site Help Center Crisis
Powered By
Treating HS/Treatments

75% HS Skin Clearance Achieved by 62% of People After 40 Weeks on Sonelokimab

Written by Ted Samson
Posted on May 5, 2026

In phase 3 clinical trials, 62 percent of people with moderate to severe hidradenitis suppurativa (HS) receiving the investigational drug sonelokimab achieved at least 75 percent skin clearance by week 40. Up to 32 percent reached complete skin clearance.

These trial results could ultimately lead to a new type of HS treatment, potentially expanding choices for people living with the condition.

What Is Sonelokimab?

Sonelokimab is an investigational biologic in a class known as nanobodies. These are smaller than traditional antibodies and are designed to target inflammation more precisely.

Share your thoughts.

🗳️ Have you tried a biologic for HS?
Yes, and it helped.
Yes, but it didn’t help.
No, but I am interested.
No, and I am not interested.

The drug is designed to block two inflammatory signals, interleukin (IL)-17A and IL-17F, which are thought to play a key role in HS inflammation.

What Did the Study Find?

The clinical trials included 838 adults with moderate to severe HS. Researchers looked at how well sonelokimab reduced inflammatory skin lesions over time.

By week 40:

  • 62 percent of participants treated with sonelokimab achieved HS Clinical Response (HiSCR) 75, meaning at least a 75 percent reduction in abscesses and inflammatory nodules without worsening of other symptoms.
  • Up to 32 percent of participants reached complete skin clearance (HiSCR100).
  • Up to 25 percent of participants achieved inflammatory remission, meaning they had no detectable abscesses, nodules, or draining tunnels at that point in the study.
  • Up to 43 percent had at least a three-point improvement in their worst skin pain on a rating scale.

Side Effects Seen in the Study

As with any treatment, sonelokimab may cause side effects.

The most common side effects reported in the first 16 weeks of use were nasopharyngitis (cold-like symptoms) in 8.6 percent of participants and oral candidiasis (a yeast infection in the mouth) in 7.3 percent.

Serious side effects occurred in about 2.5 percent of people treated with sonelokimab, though details weren’t included in the study reports.

Why This Matters for People With HS

HS can cause painful inflammatory skin lesions and, over time, can lead to scarring and tissue damage.

If longer-term data continues to look strong, sonelokimab could become another option in a treatment landscape where many people still need better HS control.

The drug’s manufacturer, MoonLake, plans to submit a biologics license application for the drug to the U.S. Food and Drug Administration in the second half of 2026.

If your HS treatment isn’t meeting your needs, consider talking with a dermatologist about your symptoms and goals, and whether new or emerging treatments may be appropriate for you.

Join the Conversation

On MyHSTeam, people share their experiences with hidradenitis suppurativa, get advice, and find support.

Have you tried a biologic treatment for HS? Let others know in the comments below.

References
  1. MoonLake Announces Week 40 Results From Its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting — MoonLake Immunotherapeutics AG
  2. Novel Therapies for Hidradenitis Suppurativa Produce Rapid, Deepening Responses — MedPage Today

Share this article
All updates must be accompanied by text or a picture.

We'd love to hear from you! Please share your name and email to post and read comments.

You'll also get the latest articles directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
65,278 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use
All updates must be accompanied by text or a picture.

Subscribe now to ask your question, get answers, and stay up to date on the latest articles.

Get updates directly to your inbox.

Subscriber Photo Subscriber Photo Subscriber Photo
65,278 members
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service.
Privacy Policy • Terms of Use

Related

  • What are the key facts I need to know about hidradenitis suppurativa? See answer
  • How do hidradenitis suppurativa symptoms typically progress over time? See answer
  • What are the current medications and treatments for hidradenitis suppurativa and when are they used? See answer
  • What are common symptoms of hidradenitis suppurativa? See answer
Prepare for COVID-19 Season: 6 Facts People With Hidradenitis Suppurativa Should Know
If you’re living with hidradenitis suppurativa (HS), staying protected against COVID-19 continues...
Prepare for COVID-19 Season: 6 Facts People With Hidradenitis Suppurativa Should Know
If you’re living with hidradenitis suppurativa (HS), staying protected against COVID-19 continues...
40% See HS Symptom Reduction in Povorcitinib Study
A new treatment called povorcitinib may help reduce symptoms of hidradenitis suppurativa (HS), ba...
40% See HS Symptom Reduction in Povorcitinib Study
A new treatment called povorcitinib may help reduce symptoms of hidradenitis suppurativa (HS), ba...
Bimekizumab Reduces Severe HS by 75% Over Two Years
New two-year data show that bimekizumab (Bimzelx) provides lasting disease control for people wit...
Bimekizumab Reduces Severe HS by 75% Over Two Years
New two-year data show that bimekizumab (Bimzelx) provides lasting disease control for people wit...
Continue with Facebook
Continue with Google
By joining, you accept our Terms of Use, and acknowledge our collection, sharing, and use of your data in accordance with our Health Data and Privacy policies.
Already a member? Log In

Thank you for subscribing!

Become a member to get even more

See answer